Sean Cunliffe
Keine laufenden Positionen mehr
Profil
Sean Cunliffe served as Director & Chief Business Officer at Sirona Biochem Corp.
in 2012.
Prior to that, he was Vice President-Marketing at Wyeth LLC.
From 2009 to 2011, he served as Vice President-Sales & Marketing at Angiotech Pharmaceuticals, Inc. and from 2005 to 2009, he was Chief Commercial Officer at Neuromed Pharmaceuticals, Inc. He also held positions as Principal at Astra Pharmaceuticals, Inc. and Glaxo, Inc. Mr. Cunliffe earned an undergraduate degree from Queen's University and an MBA from McMaster University.
Ehemalige bekannte Positionen von Sean Cunliffe
| Unternehmen | Position | Ende |
|---|---|---|
Angiotech Pharmaceuticals, Inc.
 Angiotech Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company, which engages in developing, manufacturing and marketing medical products and technologies, within the areas of interventional oncology, wound closure and ophthalmology. The company was founded by William L. Hunter and Cruz F. Tony in 1992 and is headquartered in Vancouver, Canada. | Vertrieb & Marketing | - |
Neuromed Pharmaceuticals, Inc.
 Neuromed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals, Inc. develops new and improved pain medicines. It has multiple programs aimed at addressing this important unmet medical need. Its lead product candidate, ExalgoTM is an extended release formulation of hydromorphone in phase 3 clinical development. Neuromed is also developing oral drug candidates to block N-type and T-type calcium channels, an important target directly involved in pain signaling, and includes candidates for potentially treating pain, epilepsy and hypertension. | Corporate Officer/Principal | 01.09.2009 |
| SIRONA BIOCHEM CORP. | Direktor/Vorstandsmitglied | 18.10.2012 |
| Astra Pharmaceuticals, Inc. | Corporate Officer/Principal | - |
| Glaxo, Inc. | Corporate Officer/Principal | - |
Ausbildung von Sean Cunliffe
| McMaster University | Masters Business Admin |
| Queen's University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SIRONA BIOCHEM CORP. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Wyeth Corp.
 Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Health Technology |
| Glaxo, Inc. | |
| Astra Pharmaceuticals, Inc. | |
Angiotech Pharmaceuticals, Inc.
Angiotech Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company, which engages in developing, manufacturing and marketing medical products and technologies, within the areas of interventional oncology, wound closure and ophthalmology. The company was founded by William L. Hunter and Cruz F. Tony in 1992 and is headquartered in Vancouver, Canada. | Health Technology |
Neuromed Pharmaceuticals, Inc.
Neuromed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals, Inc. develops new and improved pain medicines. It has multiple programs aimed at addressing this important unmet medical need. Its lead product candidate, ExalgoTM is an extended release formulation of hydromorphone in phase 3 clinical development. Neuromed is also developing oral drug candidates to block N-type and T-type calcium channels, an important target directly involved in pain signaling, and includes candidates for potentially treating pain, epilepsy and hypertension. | Health Technology |
